Scarica l'app Stockscreener
73.00
3.26%
-2.46
Dopo l'orario di chiusura:
73.00
Precedente Chiudi:
$75.46
Aprire:
$75.84
Volume 24 ore:
805.65K
Relative Volume:
0.86
Capitalizzazione di mercato:
$3.42B
Reddito:
$535.08M
Utile/perdita netta:
$-48.27M
Rapporto P/E:
-64.40
EPS:
-1.1335
Flusso di cassa netto:
$-31.54M
1 W Prestazione:
-3.55%
1M Prestazione:
-11.79%
6M Prestazione:
+4.11%
1 anno Prestazione:
+24.21%
Intervallo 1D:
$72.94
$75.84
Intervallo di 1 settimana:
$72.94
$79.10
Portata 52W:
$53.89
$91.53
Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile
Nome
Tarsus Pharmaceuticals Inc
Settore
Industria
Telefono
(949) 409-9820
Indirizzo
15440 LAGUNA CANYON ROAD, IRVINE
Compare TARS vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TARS
Tarsus Pharmaceuticals Inc
|
73.00 | 3.54B | 535.08M | -48.27M | -31.54M | -1.1335 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-24 | Ripresa | Oppenheimer | Outperform |
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-11-20 | Iniziato | Mizuho | Outperform |
| 2025-06-02 | Ripresa | Oppenheimer | Outperform |
| 2025-05-27 | Ripresa | H.C. Wainwright | Buy |
| 2023-11-20 | Iniziato | Goldman | Neutral |
| 2023-07-18 | Iniziato | William Blair | Outperform |
| 2023-05-18 | Iniziato | Guggenheim | Buy |
| 2022-08-01 | Iniziato | Barclays | Overweight |
| 2021-12-21 | Iniziato | H.C. Wainwright | Buy |
| 2021-11-23 | Iniziato | Oppenheimer | Outperform |
| 2020-11-10 | Iniziato | BofA Securities | Buy |
| 2020-11-10 | Iniziato | Jefferies | Buy |
| 2020-11-10 | Iniziato | Ladenburg Thalmann | Buy |
| 2020-11-10 | Iniziato | Raymond James | Strong Buy |
Mostra tutto
Tarsus Pharmaceuticals Inc Borsa (TARS) Ultime notizie
Tarsus Pharmaceuticals, Inc. (TARS) stock price, news, quote and history - Yahoo Finance Australia
Tarsus to Present 11 Abstracts at Anaheim Eye Meeting - Orange County Business Journal
Tarsus Plans to Present 11 Abstracts Highlighting New - GlobeNewswire
TARS Stock Drops After Culper Research Accuses Tarsus Of Illegal Medicare Copay Scheme - Stocktwits
TARS Reinstated by Goldman Sachs -- Rating Updated to Buy - GuruFocus
Goldman Sachs initiates Tarsus Pharmaceuticals stock coverage with buy rating - Investing.com Canada
TARS Looks 54.1% Undervalued on GF Value™ - GuruFocus
Liquidity Mapping Around (TARS) Price Events - Stock Traders Daily
Tarsus Pharmaceuticals Stock Price Forecast. Should You Buy TARS? - StockInvest.us
Pyott David E I Executes Options in Tarsus Pharmaceuticals, Retains 9,575 Shares - Kalkine Media
Tarsus Pharmaceuticals (TARS) director adds 201 shares through RSU conversion - Stock Titan
Tarsus Pharmaceuticals Insider Sold Shares Worth $979,744, According to a Recent SEC Filing - marketscreener.com
Tarsus Pharmaceuticals (TARS) director sells shares under preset plan - Stock Titan
Barclays Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Raises Target Price to $110 - Moomoo
TARS Reinstated by Barclays -- Rating Upgraded to Overweight - GuruFocus
Tarsus Pharmaceuticals Price Target Announced at $110.00/Share by Barclays - Moomoo
Nearly $1M Tarsus (NASDAQ: TARS) insider share sale planned by a company director - Stock Titan
Tarsus Pharmaceuticals (NASDAQ: TARS) Acquires Alkeus, Potential $350M Milestone Payments Included - Kalkine Media
Midday Stock Roundup: Skyworks Rises on Qorvo News - Orange County Business Journal
TARS Form 4 FilingsTarsus Pharmaceuticals, Inc. SEC Form 4 - Stock Titan
Tarsus Pharmaceuticals Finalizes Acquisition of Alkeus Pharmaceuticals with $270M Cash and Stock Deal - Kalkine Media
Tarsus Pharmaceuticals COO Neervannan Seshadri Offloads 4,564 Shares at $85 Each (NASDAQ: TARS) - Kalkine Media
Tarsus Pharmaceuticals CEO Bobak Azamian Executes Open-Market Sale of 10,000 Shares at $90.27-$91.27 (NASDAQ: TARS) - Kalkine Media
Tarsus Pharmaceuticals CMO Executes Stock Sales Under Dual 10b5-1 Trading Plans - Kalkine Media
Tarsus (NASDAQ: TARS) CEO sells 10,000 shares under 10b5-1 plan - Stock Titan
Tarsus Pharmaceuticals Insider Sold Shares Worth $387,940, According to a Recent SEC Filing - Yahoo Finance
Jefferies raises Tarsus Pharmaceuticals price target on guidance By Investing.com - Investing.com Nigeria
Tarsus Pharmaceuticals gains analyst boost afte... - Pluang
TARS Maintains by Jefferies -- Price Target Raised to $105 - GuruFocus
Tarsus Finalizes Alkeus Acquisition, Expanding Eyecare Pipeline - VisionMonday.com
Tarsus Pharmaceuticals stock hits all-time high at 85.29 USD By Investing.com - Investing.com South Africa
Tarsus Pharmaceuticals CEO Bobak R. Azamian Offloads 10,000 Shares at $80.06 Each (NASDAQ: TARS) - Kalkine Media
Officer at Tarsus (NASDAQ: TARS) lines up six-figure stock sale - Stock Titan
After recent sales, Tarsus (NASDAQ: TARS) officer's spouse plans another stock trade - Stock Titan
About $943K in stock set for sale at Tarsus (TARS) - Stock Titan
Planned Tarsus (TARS) officer sale covers 4,564 shares - Stock Titan
Tarsus Pharmaceuticals Shares Rise After Closing Alkeus Pharmaceuticals Acquisition - marketscreener.com
Tarsus Pharmaceuticals stock hits all-time high at 85.29 USD - investing.com
Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care - manilatimes.net
A potentially blinding eye disease has no FDA-approved therapy. Tarsus bought a company developing one. - Stock Titan
Tarsus Pharmaceuticals (TARS) CEO sells 10,000 shares in plan trade - Stock Titan
Shareholder plans new stock sale at Tarsus (NASDAQ: TARS) - Stock Titan
Former Tarsus (NASDAQ: TARS) officer plans another stock sale - Stock Titan
Tarsus (NASDAQ: TARS) exec plans $431K sale after recent $340K stock cash-out - Stock Titan
Tarsus (NASDAQ: TARS) officer lines up another stock sale - Stock Titan
Tarsus to Participate in Upcoming Investor Conferences - The Manila Times
Ex-officer lines up third multimillion sale in Tarsus (NASDAQ: TARS) stock - Stock Titan
Planned $340K insider stock sale at Tarsus (NASDAQ: TARS) from vested pay - Stock Titan
Form 144 | Tarsus Pharmaceuticals(TARS.US) Insider Proposes to Sell 5.75 Million in Common Stocks - Moomoo
After $3.8M sale, Tarsus (TARS) ex-officer plans more selling - Stock Titan
Tarsus (TARS) Results Check: The EPS Result Is Below Expectation in the Reported Period; Market Response: The Share Price Adds 0.16% in the Latest SessionEPS Revision Trend - careplusvn.com
Tarsus Pharmaceuticals Inc Azioni (TARS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):